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Molecular Classification of 
Enteroviruses Not Identified by 
Neutralization Tests
Hideyuki Kubo,* Nobuhiro Iritani,* and Yoshiyuki Seto* 
We isolated six viruses from patients diagnosed with aseptic meningitis or hand, foot, and mouth disease.
The cytopathic effect of these viruses on cultured cells was like that of enteroviruses. However, viral neu-
tralization tests against standard antisera were negative. Phylogenetic analysis with the complete VP4
nucleotide sequences of these 6 viruses and 29 serotypes of enteroviruses classified 3 of the viruses as
serotype echovirus type 18 (EV18) and 3 as serotype human enterovirus 71 (HEV71). These results were
confirmed by remicroneutralization tests with HEV-monospecific antisera or an additional phylogenetic
analysis with the complete VP4 nucleotide sequences. Phylogenetic analysis with complete VP4 genes is
more useful than neutralization tests with enterovirus serotype-specific antisera in identifying enterovirus
serotypes.
he human enterovirus (HEV) genus of the family Picor-
naviridae includes the human pathogens that cause a wide
spectrum of acute disease, including hand, foot, and mouth
disease (1), aseptic meningitis (2,3), encephalitis (3-6), and
neonatal sepsislike disease (7,8). Sixty-four serotypes of HEV
have been recognized antigenically by neutralization tests with
anti-HEV antibodies (9). HEVs have long been classified on
the basis of serotype-specific antisera in virus neutralization
tests (1,10), the only method available for serotyping HEVs.
However, virus neutralization is both labor- and time-inten-
sive, and antigenic variants in many serotypes of HEV can
affect test results (1). 
The HEV genome comprises a 5' nontranslated region
(NTR), a long open reading frame that encodes a protein of
approximately 2,100 amino acid residues, a short 3' NTR, and
a polyadenylated tail. The polyprotein is co- and post-transla-
tionally cleaved to yield four structural proteins: VP4, VP2,
VP3, and VP1 (1). Recently, attempts have been made to clas-
sify the HEV serotypes by using the partial nucleotide
sequences of the HEV genomes (i.e., the 5' NTR [11-13], the
VP4-VP2 junction [14-16], and VP1 [17-20]). Methods for
molecular classification of HEVs should not only identify the
serotypes rapidly but also detect antigenic variant strains or
new serotypes. A new serotype of HEV has recently been
identified by comparing the complete VP1 nucleotide
sequences; its proposed name is HEV73 (19).
To investigate the HEV serotypes of six HEV-like viruses
that were not neutralized by standard HEV typing sera, we
determined the complete VP4 nucleotide sequences of these 6
viruses and 21 HEV antigenically defined serotypes, then per-
formed phylogenetic analysis with another 8 HEV serotypes
available from GenBank. The classifications of the untypeable
viruses were confirmed by using HEV-monospecific antisera
or an additional phylogenetic analysis with the VP4
sequences. The molecular classification of HEV with the com-
plete VP4 sequences is useful for identifying the HEV sero-
types. 
Methods
Virus Isolation and the Neutralization Test 
The clinical specimens were injected into Vero, RD-18S,
or MA104 cells to isolate viruses. All cells were grown in min-
imum essential medium (MEM) containing 10% fetal bovine
serum (FBS) and maintained in MEM containing 1% to 2%
FBS after being added to 48-well plates (Sumitomo Bakelite,
Tokyo, Japan). The cells were incubated for 1 week, after
which culture fluids were passaged and incubated for another
week. Cultured cells showing cytopathic effects were regarded
as virus isolation-positive and, together with the culture super-
natant, were harvested and stored at -80°C before use. To sero-
type the viruses, microneutralization tests were performed
with antiserum pools of Lim and Benyesh-Melnick (21)
(Denka Seiken, Tokyo, Japan) or in-house monospecific
immune sera against coxsackie virus A10 (CAV10), CAV16,
and HEV71, respectively.
Viruses 
Of the six viruses that could not be identified by the neu-
tralization tests described above (Table 1), strains OC/0071,
OC/0073, and OC/00272 were isolated from patients diag-
nosed with aseptic meningitis by using RD-18S cells. OC/
00219, OC/00260, and OC/00261 were isolated from patients
diagnosed with hand, foot, and mouth disease or aseptic men-
ingitis by using Vero cells. No sera from these patients was
available for analysis. Twenty-one serotypes were isolated and
identified in our laboratory during 1995-2000 (Table 2); these
strains were used in the experiments. For additional investiga-
tions of HEV71, we used eight HEV71 strains isolated and
identified in our laboratory (Table 3).
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RNA Extraction and Reverse Transcription
Viral RNAs were extracted from the cell-culture superna-
tants by using ISOGEN-LS (Nippon Gene, Tokyo, Japan).
cDNAs were synthesized with an Omniscript Reverse Tran-
scriptase Kit (QIAGEN K.K., Tokyo, Japan) according to the
manufacturer’s instructions. The primers used for the synthesis
were EVP-2 (5'-CCTCCGGCCCCTGAATGCGGCTAAT-3'
relative to nt 444-468 in the genome of Poliovirus (PV) Sabin
1 strain) (22) and OL68-1 (5'-GGTAAYTTCCACCAC-
CANCC-3' relative to nt 1178-1197 of Sabin 1), as described
(23).
Polymerase Chain Reaction Amplification of cDNAs 
Polymerase chain reaction (PCR) was performed by using
2 µL of each cDNA in a 50-µL reaction mixture containing 1.5
U of Taq DNA polymerase (Takara Shuzo, Shiga, Japan), 20
pmol of EVP-2 primer, and 20 pmol of OL68-1 primer. Each
reaction was incubated in a GeneAmp 9700 thermal cycler
(Applied Biosystems, Foster City, CA) according to the fol-
lowing protocol: 5 minutes at 95°C, 40 cycles of 95°C for 30
seconds, 68°C for 30 seconds, 72°C for 1 minute, and then at
72°C for 5 minutes. After the appearance of approximately
750 bp-specific amplified fragments was confirmed by agar-
ose gel electrophoresis, the amplicons were purified with a
QIAquick PCR purification kit (QIAGEN).
DNA Sequence Analysis
Approximately 100 ng of purified amplicon was used in
the reaction with the BigDye Terminator Cycle Sequencing FS
Ready Reaction Kit (Applied Biosystems), and DNA sequenc-
ing was performed by using an ABI PRISM 310 DNA
sequencer (Applied Biosystems). All DNA sequencings were
performed on both strands using EVP-4 (5'-CTACTTTGGGT-
GTCCGTGTT-3' relative to nt 541-560 in the genome of PV
Sabin 1 strain) as the forward primer and OL68-1 as the
reverse primer (23). Sequencer software (version 3.0; Hitachi
Software, Tokyo, Japan) was used to determine the approxi-
mately 600-bp nucleotide sequence spanning 5' NTR to one
third of VP2 (including all of VP4), translate nucleotide
sequence to amino acid sequence, and decide the complete
VP4 coding sequence of each virus.
Phylogenetic Analysis
A phylogenetic tree based on the complete VP4 nucleotide
sequence was constructed by the neighbor-joining method (24)
as implemented with the CLUSTAL X program (version
1.63b, December 1997; http://www-igbmc.u-strasbg.fr/Bio-
Info/ClustalX/). The reliability of the neighbor-joining tree
was estimated by bootstrap analysis with 1,000 pseudorepli-
cate datasets. The complete VP4 sequences of eight HEV sero-
types not isolated in our laboratory were obtained from
GenBank and included in the HEV analysis. Complete VP4
nucleotide sequences of another 18 HEV71 strains were
obtained from GenBank and used in the phylogenetic analysis.
Remicroneutralization Tests
According to results of HEV phylogenetic analysis with
the complete VP4 nucleotide sequences, remicroneutralization
tests using monospecific antiserum against echovirus 18
(EV18; Denka Seiken), or HEV71 (anti-HEV71/BrCr and
Table 1. Unidentified enterovirus strains and patient information, 
Osaka, Japan, 2000
Strain
Patient age 
(years) Specimen
Date of 
sampling
Clinical 
symptoms
Isolated 
cells
OC/0071 2 Stool 5/11/2000 AMa RD-18S
OC/0073 2b  CSF 5/11/2000 AM RD-18S
OC/00219 0 Throat 
swab
7/7/2000 HFMD Vero
OC/00260 0 Throat 
swab
7/18/2000 HFMD, 
AM
Vero
OC/00261 0c Stool 7/18/2000 HFMD, 
AM
Vero
OC/00272 6 Stool 7/18/2000 AM RD-18S
aAM = aseptic meningitis; CSF = cerebrospinal fluid; HFMD = hand, foot, and mouth 
disease.
bSame patient as OC/0071.
cSame patient as OC/00260.
Table 2. Characteristics of 21 human enterovirus (HEV) serotypes 
antigenically defined, Osaka, Japan, 1995–2000
HEV 
serotype Strain
Age
(years) Specimen
Date of 
sampling
Isolated 
cells
PV1 OC/00417 0 Throat swab 10/13/2000 Vero
PV2 OC/00138 0 Stool 6/10/2000 Vero
PV3 OC/99355 0 Nasal mucus 11/8/1999 Vero
EV3 OC/00467 7 Stool 11/13/2000 RD-18S
EV6 OC/99350 0 Stool 11/8/1999 RD-18S
EV7 OC/96221 7 Throat  swab 7/22/1996 MA104
EV9 OC/00129 3 CSF 6/8/2000 RD-18S
EV11 OC/98535 3 Stool 9/23/1998 RD-18S
EV16 OC/95378 1 Throat swab 9/11/1995 MA104
EV18 OC/99-
Hanasaka
7 Stool 11/8/1999 RD-18S
EV25 OC/00263 0 Stool 7/17/2000 RD-18S
EV30 OC/97633 1 Stool 9/29/1997 RD-18S
CAV9 OC/96234 4 CSFa  8/2/1996 RD-18S
CAV16 OC/00351 NA Throat  swab 8/31/2000 Vero
CBV1 OC/00364 0 CSF 9/6/2000 Vero
CBV2 OC/99284 0 Stool 9/11/1999 RD-18S
CBV3 OC/97620 6 CSF 9/19/1997 RD-18S
CBV4 OC/00362 1 Stool 9/8/2000 Vero
CBV5 OC/00223 0 Throat  swab 7/7/2000 Vero
CBV6 OC/00325 0 CSF 8/8/2000 Vero
HEV71 OC/00168 2 Throat swab 6/21/2000 Vero
a CSF = Cerebrospinal fluid; NA = not available.RESEARCH
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anti-HEV71/C7 sera; both supplied by the National Institute of
Infectious Diseases, Japan) were performed to confirm the
serotype of the untypeable strains from the first microneutral-
ization assay.
Complete VP1 Nucleotide Compared with 
Deduced Amino Acid Sequences of HEV71 Strains
The complete VP1 nucleotide sequences of HEV71 strains
OC/00168, 0C/00219, OC/00260, and OC/00261 were deter-
mined by the same procedure described above, except for the
primers. The primers used for the analysis of VP1 nucleotide
sequence were 71F2399 (5' -AGAAYTTYACCAT-
GAAACTG-3' relative to nt 2380-2399 in the genome of
HEV71 MS/7423/87 strain [25]; the nucleotide positions of
the following are also relative to this strain: 71F2793 (5'-
AGACATAACTGGYTACGCCAC-3' nt 2774-2793) and
71F3042 (5'-CATGTCACCYGCGAGCGCTT-3' nt 3023-
3042) as the forward, 71R2712 (5'-CTACCAARCCTGC-
CCTACTG-3' nt 2693-2712), 71R3066 (5'-GGTACCCGTCG-
TAAAACCAC-3' nt 3047-3066) and 71R3376 (5'-
AAGTTGCCCACGTAGATGGC-3' nt 3357-3376) as the
reverse. The VP1 nucleotide sequence of HEV71 BrCr strain
(25) was obtained from GenBank. Sequencer software (ver-
sion 3.0; Hitachi Software) was used for determination and
comparison of the complete VP1 nucleotide and deduced
amino acid sequences of these HEV71 strains. 
Results
Determination of Complete VP4 Nucleotide 
Sequences of HEVs
During May to July 2000, six viruses submitted to our lab-
oratory (OC/0071, OC/0073, OC/00219, OC/00260, OC/
00261, and OC/00272) could not be neutralized by standard
pools of HEV typing sera and three antimonospecific sera
(Table 1). However, the cytopathic effects of these viruses on
RD-18S or Vero cells were all HEV-like (data not shown). To
identify the serotypes of these untypeable HEV-like viruses by
a method other than the neutralization assay, we determined
the complete VP4 nucleotide sequences of all 6 strains and
another 21 HEV serotypes identified in our laboratory over the
past 6 years. The 3' end of the VP4 gene of each virus was
determined from the deduced amino acid sequences as
described (26,27). The complete VP4 nucleotide sequences of
all HEV strains used in this study were 207 nt long, and the
deduced amino acid sequences of all VP4 proteins were 69
amino acids long (data not shown).
Phylogenetic Analysis of HEVs
A phylogenetic tree was constructed based on the complete
VP4 nucleotide sequences of the 6 HEV-like untypeable
strains, the 21 HEV serotypes identified in our laboratory as
prototype strains, and another 8 HEV serotypes available from
the GenBank database (Figure 1). The 29 different HEV sero-
types defined antigenically were clustered in four distinct lin-
eages, as described (23). Three of the six untypeable strains
(OC/0071, OC/0073, and OC/00272) were classified nearest to
EV18. The VP4 nucleotide sequences of strains OC/0071 and
OC/0073 were identical. The VP4 gene sequence of OC/00272
was the same as that of OC/99-Hanasaka, which was used as a
prototype strain for EV18. The nucleotide sequences of these
two clusters differed by 5 nt, but the deduced amino acid
sequences were the same (data not shown). The other three
untypeable strains (OC/00219, OC/00260, and OC/00261)
were classified nearest to HEV71. The VP4 sequence of OC/
00219 was the same as that of OC/00168, which was used as a
prototype strain for HEV71. The VP4 nucleotide sequences of
OC/00260 and OC/00261 were identical. The difference
between these two clusters was 11 nt. The deduced amino acid
sequences were the same (data not shown).
Remicroneutralization Tests
According to the results of the phylogenetic analysis based
on the complete VP4 nucleotide sequences, remicroneutraliza-
tion tests were performed. Microneutralization tests using the
monospecific immune serum for EV18 were done against OC/
0071, OC/0073, and OC/00272, and this serum neutralized
these viruses. The same tests, using the two species of mono-
specific immune serum, anti-HEV71/BrCr and anti-HEV71/
C7, were performed against OC/00219, OC/00260, and OC/
00261, but neither serum neutralized the viruses (Table 4). 
Table 3. Characteristics of eight human enterovirus (HEV)71 strains, as antigenically defined, Osaka, Japan, 2000
Strain Age(years) Specimen Date of sampling Clinical symptoms Isolated cells
OC/9632 NAa  Stool 4/11/1996 HFMD MA104
OC/99-Ikeda 6 Stool 9/11/1999 HFMD, AM Vero
OC/0078 1 Throat swab 5/18/2000 HFMD, AM Vero
OC/0080 NA Stool 5/9/2000 Diarrhea Vero
OC/0096 5 CSF 5/25/2000 Diarrhea, AM Vero
OC/00114 0 CSF 5/31/2000 Fever Vero
OC/00125 6 Throat swab 6/7/2000 Encephalitis Vero
OC/00168 4 Throat swab 6/21/2000 Herpangina Vero
a NA = Not available; HFMD = Hand, foot, and mouth disease; AM = aseptic meningitis; CSF = cerebrospinal fluid.Emerging Infectious Diseases  •  Vol. 8, No. 3, March 2002 301
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Phylogenetic Analysis of HEV71 Strains
To establish whether OC/00219, OC/00260, and OC/
00261 belong to HEV71, we used another phylogenetic analy-
sis based on the complete VP4 nucleotide sequences of various
HEV71 strains (Figure 2). In this analysis, we examined eight
HEV71 strains isolated and identified in our laboratory from
1996 to 2000 (Table 3). All these HEV71 strains except for
OC/9632 were identified by microneutralization tests with anti
HEV71/BrCr serum (data not shown). Of the HEV71 strains
available from GenBank, two were isolated in the United
States in 1970 and 1987, respectively (25), four in Malaysia in
1997 (15), one in Singapore in 1998 (28), eight in Taiwan in
1998 (15,28), two in the United Kingdom in 1999, and one in
China (year unknown). The HEV71 strains were clustered in
three distinct genotypes, designated A, B, and C. The genotype
nomenclature of HEV71 strains for phylogenetic analyses
based on the VP1 (17,25,28) and VP4 (29) nucleotide
sequences has been reported, and the results (Figure 2) were
consistent with previous findings. Among the HEV71 strains
that were identified in our laboratory, only OC/99-Ikeda was
classified in genotype C. Seven of eight strains identified in
our laboratory by neutralization tests were classified in geno-
type B; five of these had the same VP4 nucleotide sequence.
OC/00219, OC/00260, and OC/00261 were also classified in
this genotype. This result demonstrated that strains OC/00219,
OC/00260, and OC/00261 were HEV71 serotypes.
Comparison of the Complete VP1 Nucleotide and 
Deduced Amino Acid Sequences of HEV71 Strains
Strains OC/00219, OC/00260, and OC/00261 were classi-
fied in HEV71 by the phylogenetic analysis, although these
viruses were not neutralized by monospecific anti-HEV71
sera. Because the VP1 protein contains a number of important
neutralization sites (1,30), we determined the complete VP1
nucleotide sequences and compared the deduced amino acid
sequences of OC/00219, OC/00260, and OC/00261. OC/
00168 used as a prototype strain for HEV71 was also analyzed
because this strain was neutralized by anti-HEV71/BrCr
serum; moreover, its VP4 gene was the same as that of OC/
00219 (Figure 2). The complete VP1 nucleotide sequences of
these strains were 891 nt long, and the deduced amino acid
sequences were 297 amino acids long. The differences of VP1
nucleotide sequences were 4 to 42 nt (0.4% to 4.7%), and the
difference of deduced amino acid sequences was one amino
acid (0.3%) among these viruses. The differences of VP1
nucleotide sequences between OC/00168 and OC/00219 were
4 nt (0.4%), and the deduced VP1 amino acid sequences of
these strains were the same. The VP1 nucleotide and deduced
amino acid sequences of OC/00260 and OC/00261 were
Figure 1. Phylogenetic analysis based on the human enterovirus (HEV)
VP4 nucleotide sequences. The phylogenetic tree was constructed by
the neighbor-joining method as implemented in CLUSTAL X program
(version 1.63b). The marker denotes a measurement of the relative
phylogenetic distance. The VP4 sequences of eight HEV serotypes
described below are available from GenBank. The strain name and
accession number are shown in parentheses: HEV1 (Bryson,
AF250874), HEV12 (Travis, NC 001810), echovirus 26 (EV26, Coro-
nel, AF117697), EV29 (JV-10, AF117698), coxsackie virus A2 (CAV2;
Epsom/14448/99, AJ2296215), CAV21 (Coe, NC 001428), CAV24
(EH24/70, D90457), and HEV70 (J670/71, D00820).
Table 4. Results of re-microneutralization tests with human enterovi-
rus (HEV) monospecific antiserum, Osaka, Japan, 2000
Strain
Isolated 
cells
Predicted 
HEV 
Serotypea
HEV monospecific antiserum
Anti-
EV18
Anti-
HEV71/
BrCr
Anti-
HEV71/C7
OC/0071 RD-18S EV18b +N D N D
OC/0073 RD-18S EV18 + ND ND
OC/00219 Vero HEV71 ND -- --
OC/00260 Vero HEV71 ND -- --
OC/00261 Vero HEV71 ND -- --
OC/00272 RD-18S EV18 + ND ND
aSerotypes were predicted from the phylogenetic analysis in Figure 1.
b EV18 = echovirus 18;  ND = Test not done.RESEARCH
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identical (data not shown). The deduced VP1 amino acid
sequences of these four strains were compared with that of
BrCr (Table 5). There were 18 amino acid (6%) differences
between BrCr and other strains. The different amino acid posi-
tions of strains OC/00168, OC/00219, OC/00260, and OC/
00261 against BrCr were the same. Any mutated residues dis-
tinguishable BrCr and OC/00168 from OC/00219, OC/00260,
and OC/00261 were not recognized in the VP1 amino acid
sequences.
Discussion
The serotype identification of HEVs has been performed
by microneutralization tests using standard HEV antiserum
pools (1,10). Since >60 serotypes of HEV are known to infect
humans (1,19), the HEV serotype is almost impossible to iden-
tify by using monospecific antiserum from the first microneu-
tralization test. Furthermore, the neutralization test is labor-
intensive and time-consuming, requiring several weeks. As an
alternative, identification based on nucleotide sequences has
been used successfully in several laboratories (15,19,20,
23,29,31-35). To investigate the serotypes of the six untype-
able HEV-like viruses that were not neutralized by the stan-
dard HEV antisera, we used phylogenetic analyses based on
the complete VP4 nucleotide sequences of HEVs and were
able to determine the serotype of each virus in the light of
these results. OC/0071, OC/0073, and OC/00272 were thought
to be EV18 strains by the phylogenetic analysis (Figure 1) and
were neutralized by the monospecific anti-EV18 serum. These
results indicate that the phylogenetic analysis based on the
VP4 nucleotide sequence is consistent with the result of the
microneutralization tests using the serotype-specific sera. OC/
00219, OC/00260, and OC/00261 were thought to be HEV71
strains by the same analysis (Figure 1), but these viruses were
not neutralized by the two monospecific anti-HEV71 sera. The
phylogenetic analysis based on the HEV71 VP4 sequences
confirmed that these viruses were HEV71 strains belonging to
genotype B (Figure 2). We considered that OC/00219, OC/
00260, and OC/00261 were all HEV71 strains not neutralized
Figure 2. Phylogenetic analysis based on the human enterovirus 71
(HEV71) VP4 nucleotide sequences. The phylogenetic tree was con-
structed as described in the Figure 1 legend. The genotypes of the
HEV71 cluster are denoted on the right. The VP4 sequences of 18
HEV71 strains available from GenBank are denoted by strain name,
followed by the country and year isolated. Abbreviations for countries
are as follows: US, United States; ML, Malaysia; CH, China; UK, United
Kingdom; TW, Taiwan; and SG, Singapore. The accession numbers are
as follows: BrCr; U22521, Tainan/6092/98; AF304459, 1425a/98/tw;
AF176044, NCKU9822; AF136379, TW/2086/98; AF119796, 5142/98;
AB037251, TW/2272/98; AF119795, HO106/98; AB037252, Epsom/
815/99; AJ296213, SHZH9; AF302996, KED005; AB051334, E1387;
AB051313, 13/Sin/98; AF251358, SK036; AB051333, KED60;
AB051335, SK026; AB051332, MS/7423/87; U22522, Epsom/10620/
99; and AJ296214.
Table 5. Differences in deduced VP1 amino acid sequences (aa 1-
297) of human enterovirus 71 strains BrCr, OC/00168, OC/00219, 
OC/00260, and OC/00261, Osaka, Japan, 2000
Amino acid 
position
Strain
BrCra OC/00168 OC/00219 OC/00260 OC/00261
18 Lys Arg Arg Arg Arg
22 Pro Gln Gln Gln Gln
30 Pro Gln Gln Gln Gln
31 Asp Asn Asn Asn Asn
43 Lys Glu Glu Glu Glu
58 Ala Thr Thr Thr Thr
98 Lys Glu Glu Glu Glu
145 Arg Glu Glu Glu Glu
164 Asp Glu Glu Glu Glu
167 Asp Glu Glu Glu Glu
172 Pro Gln Gln Gln Gln
183 Ser Leu Leu Leu Leu
184 Ser Thr Thr Thr Thr
244 Glu Lys Lys Lys Lys
246 Ser Pro Pro Pro Pro
249 Ile Val Val Val Val
275 Ser Ala Ala Ala Ala
282 Asp Asn Asn Ser Ser
aVP1 nucleotide sequence was obtained from GenBank (accession no. U22521) and 
translated into the deduced amino acid sequence. Emerging Infectious Diseases  •  Vol. 8, No. 3, March 2002 303
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by anti- HEV71/BrCr and anti-HEV71/C7 sera, both available
as standard monospecific anti HEV71 serum in Japan. These
results also indicate that phylogenetic analysis with the VP4
sequences of HEVs can identify the serotypes in the same way
as neutralization tests with HEV serotype-specific antisera. We
are now preparing antiimmune sera against OC/00219, OC/
00260, and OC/00261, respectively, to confirm antigenically
that these are the prime strains of HEV71 neutralized by anti-
HEV71/BrCr serum. 
Oberste et al. have shown that HEV VP1 nucleotide
sequences correlate with antigenically defined serotypes and
have demonstrated the utility of VP1 sequences as a molecular
surrogate for antigenic type (19,35). They have also shown
that the VP1 sequences have a better correlation with HEV
serotypes than the 5' NTR or the VP4-VP2 junction (36). The
phylogenetic analysis based on the VP4 sequences we have
described also correlates well with HEV serotypings by anti-
immune sera. We used 21 HEV serotypes antigenically
defined in our laboratory and another 8 strains available from
GenBank as prototype strains in this analysis. We do not know
whether 29 serotypes are sufficient for the phylogenetic analy-
sis of HEV, as there are >60 serotypes. The good result of
HEV phylogenetic classification based on the VP4 sequences
might depend on the prototype numbers (29 of 64 serotypes)
that we used. Ishiko et al., who performed HEV phylogenetic
analyses based on VP4 sequences (23), used 45 HEV sero-
types as prototype strains and obtained a phylogenetic tree
similar to ours (Figure 1) except for a difference in the proto-
type strain numbers. Another phylogenetic analysis based on
the VP4 sequences in this article was performed against the
HEV71 strains (Figure 2). For this analysis, the HEV71 strains
were clustered in three distinct genotypes, and the nomencla-
ture was almost the same as for the HEV71 analyses based on
the VP1 nucleotide sequences (17,25). Recently, Chu et al.
also reported the appropriateness of the phylogenetic analysis
with the VP4 sequences for the molecular epidemiology of
HEV71 outbreak in Taiwan in 1998 (29). These results suggest
that the phylogenetic analysis based on the VP4 nucleotide
sequences is also useful as a molecular surrogate for antigenic
HEV serotyping. The analysis was more convenient based on
the VP4 sequences than the VP1 sequences, since the com-
plete VP4 sequence is 207 nt and the complete VP1 sequences
are 834 to 951 nt (35), although the 3' third of the VP1
sequence of 365 nt was used (32). 
The VP4 nucleotide sequences of OC/99-Hanasaka and
OC/00272 were identical, but the results of neutralization
assays were different. OC/99-Hanasaka was easily neutralized
by HEV pooled sera against EV18, but OC/00272 was not.
The same results were observed for strains OC/00168 and OC/
00219 HEV71, i.e., the results of their neutralization tests dif-
fered in spite of the VP4 sequence identity. These results indi-
cate that the VP4 nucleotide sequences are highly conserved
even though the neutralizable epitopes are antigenic variants.
We compared the VP4 nucleotide and deduced amino acid dif-
ferences of HEV71 strains, BrCr (25), E1387 (15), OC/9632,
OC/99-Ikeda, OC/0078, OC/00219, and OC/00260. HEV71
genotypes indicated 1 to 37 nt (0.5% to 17.9%) differences.
However, we found no amino acid differences (100% identity)
(Table 6). Complete homology of the HEV71 VP4-deduced
amino acid sequences has also been described (20,29), and
Singh et al. demonstrated amino acid substitutions in the VP2
and VP3 regions, with the greatest variation in VP1 (20).
These results indicate that VP4 is the most stable protein;
accordingly, VP4 genes will be suitable for the molecular iden-
tification of HEV serotypes in the future.
VP4 is not exposed on the outer surface of the capsid, and
no neutralizable epitopes appear to exist in VP4. On the other
hand, VP1, VP2, and VP3 are outer capsid proteins and con-
tain neutralizable epitopes (37,38). A number of important
neutralization epitopes may exist on VP1 (1,30,39). To con-
firm the important neutralization sites on VP1, we compared
the deduced VP1 amino acid sequences of HEV71 strains OC/
00168, OC/00219, OC/00260, and OC/00261. OC/00168 was
neutralized by anti-HEV71/BrCr serum, while OC/00219, OC/
00260, and OC/00261 were not. Comparison of the deduced
VP1 amino acid sequences showed that no mutated residues
on the VP1 region corresponded to the result of the neutraliza-
tion tests. This result indicates that either the important neu-
tralization epiotopes for anti-HEV71/BrCr serum do not exist
on the VP1 protein, or the epitopes are specifically masked in
the cases of OC/00219, OC/00260, and OC/00261. Further
analysis against the VP2 and VP3 regions of these strains
should allow interpretation of these findings. 
Table 6. Number of nucleotide and deduced amino acid differences between the VP4 genes of human enterovirus 71 strains,a Osaka, Japan, 2000
BrCr E1387 OC/9632 OC/0078 OC/00219 OC/00260 OC/99-Ikeda
BrCr 33 37 36 37 32 34
E1387 0 10 7 8 7 33
OC/9632 0 0 13 14 15 37
OC/0078 0 0 0 1 10 37
OC/00219 0 0 0 0 11 36
OC/00260 0 0 0 0 0 34
OC/99-Ikeda 0 0 0 0 0 0
aNucleotide numbers are given above the diagonal and amino acid numbers below it.RESEARCH
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